🇺🇸 SECGH Research PLCDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 10-09 19:00:37·⟳ 抓取 09:09:45 +1d14h·⚡ 决策 10-11 09:18:51 +9m06s·16.5 天前
GH Research 6-K仅预告将在ECNP年会展示GH001两项临床试验海报，未含任何新数据或新事实
该6-K是例行学术会议海报日程公告，正文不含任何结果、指引或交易类信息；核心TRD-201数据为既往已披露并已发表内容，BD-202新数据未在本备案中给出，无法据此建立方向性edge。
📄 原文GH Research PLC↗ 原文
----- ef20083476_6k.htm ----- 6-K 1 ef20083476_6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,…
不做 GH Research PLC（GHRS.US）
6-K为例行ECNP会议海报日程预告，无新增临床/商业事实，TRD-201数据早已公开，BD-202新读数未在备案中披露；无可据以交易的edge，且周末闭市无法执行，等含实质结果的新闻稿再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
SEC 6-K仅预告GH Research在ECNP 2026展示两张GH001海报，无新数据；TRD-201为旧数据，BD-202内容未披露，属无增量事实的例行会议公告，不做。
消息传播链
- 节点
主要风险
- BD-202海报或周末新闻稿若含超预期新读数，可能在周一开盘引发跳空，但该信息不在本6-K内，无法提前据以交易
- 小盘临床期biotech对会议数据反应波动大，凭日程预告抢跑属投机
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
未发现本6-K附带任何新阳性结果或监管进展；TRD-201为旧数据，缺乏新增利多支撑
检索:GH Research GH001 ECNP 2026 new data BD-202 results 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不影响标的选择，直接支持AVOID
方向:未评估：无增量事实的例行学术会议预告不构成可交易事件，无需先例校准
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`gh research 6-k october 9 2026 ecnp munich clinical data | gh research ecnp 2026 gh001-trd-201 gh001-bd-202 poster presentation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - web_search 成功 doubao_search · 1,369 ms
豆包搜索结果（原始查询:GH Research GH001 ECNP 2026 TRD-201 BD-202 data presentation；API SearchType:web）
原文全文
展开原文 · 1,591 字
----- ef20083476_6k.htm -----
6-K
1
ef20083476_6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
☒
Form 40-F
☐
GH Research PLC (the “Company”) announces the presentation of data from its
GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 10-13, 2026, in Munich, Germany. The data will be presented in three
posters during Poster Session 2 on October 11, 2026, by Prof. Wiesław J. Cubała, Prof. Bernhard T.
Baune, and Dr. Max de Leeuw.
The Company will also sponsor an industry satellite symposium titled
“Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants” at ECNP on October 10, 2026.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
GH Research PLC
Date: October 9, 2026
By:
/s/ Magnus Halle
Name:
Magnus Halle
Title:
Company Secretary
3
6-K
1
ef20083476_6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
☒
Form 40-F
☐
GH Research PLC (the “Company”) announces the presentation of data from its
GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 10-13, 2026, in Munich, Germany. The data will be presented in three
posters during Poster Session 2 on October 11, 2026, by Prof. Wiesław J. Cubała, Prof. Bernhard T.
Baune, and Dr. Max de Leeuw.
The Company will also sponsor an industry satellite symposium titled
“Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants” at ECNP on October 10, 2026.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
GH Research PLC
Date: October 9, 2026
By:
/s/ Magnus Halle
Name:
Magnus Halle
Title:
Company Secretary
3
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
c61c8c71f3· 2026-10-11 09:18 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前